BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s approved treatment for achondroplasia.

​Achondroplasia is a genetic condition that causes dwarfism and stunted growth in children. The recent data reported by the company suggests that starting treatment before the age of 2 years maximizes benefits, including height gains, better body proportions, and arm span. The data showed that kids under 6 months, starting VOXZOGO, showed sustained improvements over 4 years.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) noted that data suggest that more than 5,000 kids in 50+ countries have used VOXZOGO. Data from Japan, Europe, and the US suggest strong results. For instance, kids under 2 years in Japan gained 9.91 cm in 12 months, and 15.62 cm in 24 months.

​BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the risk and potential of BMRN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMRN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.